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Protection of cattle from alcelaphine herpesvirus-1 (AlHV-1)-induced malignant catarrhal fever (MCF) has been
described previously, using an attenuated virus vaccine in an unlicensed adjuvant. The vaccine was hypothesised to
induce a protective barrier of virus-neutralising antibody in the oro-nasal region, supported by the observation of
high titre neutralising antibodies in nasal secretions of protected animals. Here we describe further analysis of this
vaccine strategy, studying the effectiveness of the vaccine formulated with a licensed adjuvant; the duration of
immunity induced; and the virus-specific antibody responses in plasma and nasal secretions. The results presented
here show that the attenuated AlHV-1 vaccine in a licensed adjuvant protected cattle from fatal intranasal challenge
with pathogenic AlHV-1 at three or six months. In addition, animals protected from MCF had significantly higher
initial anti-viral antibody titres than animals that succumbed to disease; and these antibody titres remained
relatively stable after challenge, while titres in vaccinated animals with MCF increased significantly prior to the onset
of clinical disease. These data support the view that a mucosal barrier of neutralising antibody blocks infection of
vaccinated animals and suggests that the magnitude of the initial response may correlate with long-term
protection. Interestingly, the high titre virus-neutralising antibody responses seen in animals that succumbed to
MCF after vaccination were not protective.Introduction
Malignant catarrhal fever (MCF) is a fatal disease of cat-
tle and other ungulates caused by gamma-herpesviruses
of the genus macavirus, including alcelaphine herpes-
virus 1 (AlHV-1) and ovine herpesvirus 2 (OvHV-2)
[1,2]. These viruses infect their reservoir hosts (wilde-
beest for AlHV-1 and sheep for OvHV-2) efficiently and
without apparent disease but cause lymphoproliferative
disease that is generally fatal when they infect suscep-
tible hosts such as cattle, deer and bison. MCF is found
worldwide wherever susceptible hosts mix with reservoir
species [1].* Correspondence: george.russell@moredun.ac.uk
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reproduction in any medium, provided the orThe AlHV-1 and OvHV-2 genomes have been com-
pletely sequenced, revealing that they are highly-related
viruses [3,4]. Both viruses cause MCF with similar path-
ology in susceptible animals that include laboratory spe-
cies such as hamster and rabbit [5-7]. In cattle, MCF is
characterised by fever, generalised lymphadenopathy,
nasal and ocular discharge, and erosions of mucosal epi-
thelia throughout the gastrointestinal tract. Death can
occur within a few days or weeks after the first clinical
signs. Characteristic lesions of this disease include non-
purulent vasculitis and interstitial infiltration of lymph-
oid cells in most tissues, which may be associated with
the presence of ulcers at epithelial surfaces [8,9].
Despite the severity of the lesions associated with MCF,
virus-infected cells in the tissues have been difficult to de-
tect, suggesting they were of low frequency [10]. However,
recent results in AlHV-1 and OvHV-2-infected cattle,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are more frequent [11,12]. These infected cells may be
the source of the large granular lymphocytes that can be
cultured from the tissues of MCF-affected animals. These
cell lines comprise> 90% infected cells that have unre-
stricted cytotoxic activity for a variety of target cells
[13-16].
Current control measures for MCF rely on minimizing
contact between carrier animals and susceptible live-
stock. For AlHV-1 MCF, in areas close to wildebeest mi-
gration routes in east Africa, this has the effect of
driving pastoralist cattle to poorer grazing where the
risks of other diseases such as trypanosomiasis or east
coast fever are increased, with consequent poor product-
ivity [17,18]. Thus, improved control measures for MCF,
particularly an effective vaccine, would significantly im-
prove the livelihoods of subsistence-level pastoralists.
Similarly, OvHV-2 MCF is a problem in farmed bison,
deer and susceptible cattle worldwide, and a vaccine is
eagerly sought. Early attempts to immunise cattle using
live or inactivated formulations of attenuated strains of
AlHV-1 were either unsuccessful or gave equivocal
results [19,20]. However, we have recently developed an
immunisation strategy that uses prime and boost immu-
nisations of attenuated AlHV-1 in adjuvant intramuscu-
larly in the upper neck to stimulate a mucosal barrier of
virus–neutralising antibody in the oro-nasal pharyngeal
region [21]. This approach successfully protected cattle
challenged intranasally with a fatal dose of virulent
AlHV-1. This original study used Freunds’ adjuvant and
a relatively early time point for challenge (10 weeks after
priming immunisation, 6 weeks after booster immunisa-
tion) but demonstrated that reliable protection against
AlHV-1 MCF could be achieved.
In the present study, we wished to determine: firstly,
whether the licensed oil-and-water adjuvant Emulsigen
would facilitate protective immunity to AlHV-1; sec-
ondly, the duration of immunity; and thirdly, whether
the degree of protective immunity correlated with virus-
specific antibody responses locally (nasal secretions) or
systemically (blood plasma). In these immunisation
experiments AlHV-1 was used as, unlike OvHV-2, cell-
free attenuated and virulent virus could be obtained
from tissue culture and used to immunise cattle and
challenge them respectively [20].
Materials and methods
Viruses and adjuvant
The strains of AlHV-1 used for vaccination and chal-
lenge were as described previously [21]. Briefly, the viru-
lent C500 strain virus was collected from cultures of
bovine turbinate (BT) cells infected with a cell suspen-
sion derived from pooled lymphoid tissue from rabbits
infected with AlHV-1 C500 that had developed MCF.Infected BT cell cultures were passaged onto fresh BT
cells by a 1:4 split four times at peak cytopathic effect
(approximately weekly) after which virulent virus was
harvested from culture supernatants and cells following
three rounds of freeze-thaw treatment. Cell-free virus
supernatant was stored at -80°C in batches and repre-
sentative aliquots of each batch were titrated to allow
calculation of the appropriate challenge dose. Titration
measured 50% tissue-culture-infectious dose (TCID50) as
described previously [21,22]. Pathogenic virus challenge
in this experiment was by intranasal inoculation of
10 ml of virus suspension with titre approximately 104
TCID50/mL.
The attenuated AlHV-1 C500 strain at passage> 1000
was used as the source of virus for immunisation [23].
This cell-free virus was obtained from BT cell culture
supernatants, clarified by centrifugation and stored in
batches at -80 °C. Representative aliquots of attenuated
AlHV-1 were titrated as described for virulent AlHV-1.
Emulsigen is an oil-in-water adjuvant that has no
ingredients of animal origin [24]. It contains micron-
sized oil droplets with a high surface area available for
antigen coating and does not cause adverse reactions at
the injection site. Titration of the attenuated AlHV-1
virus in combination with adjuvant showed that 20%
Emulsigen did not reduce the titre of the virus and that
the adjuvant was not toxic to BT cells (data not shown).
Thus, the AlHV-1-Emulsigen combination can be
classed as an adjuvanted live vaccine.
Animals
Disease-free and MCF seronegative male Ayrshire, Hol-
stein or Friesian-Holstein cross calves of approximately
7 months of age were used in the experiments. The ani-
mal experiments were carried out with the approval of
the Moredun Research Institute’s experiments and ethics
committee and complied fully with the Home Office of
Great Britain and Northern Ireland “Animals (Scientific
Procedures) Act 1986”. Animals were assigned to experi-
mental groups randomly, after taking age and breed into
account. After virus challenge, animal rectal tempera-
tures were measured daily and clinical scoring was done
daily after the onset of fever (temperature> 40°C). Clin-
ical scoring, based on temperature, body condition, ocu-
lar and nasal pathology, was used to ensure that all
animals were euthanized at the onset of moderate clin-
ical signs with an overdose of intravenous sodium
pentabarbitone.
Immunisation study design
Two vaccine studies are presented here. In the first
study, the efficacy of the licensed adjuvant Emulsigen
(MVP, Omaha, USA) was addressed (Table 1; group 1).
Eight calves in this group were intranasally challenged















805 1 Vaccine 63 100 pos MCF 37
789 1 Vaccine 63 103 pos MCF 40
792 1 Vaccine 63 119 pos MCF 56
568 1 Vaccine 63 139 neg -
570 1 Vaccine 63 139 neg -
785 1 Vaccine 63 140 neg -
822 1 Vaccine 63 140 neg -
807 1 Vaccine 63 140 neg -
575 1 Control 63 84 pos MCF 21
787 1 Control 63 93 pos MCF 30
814 1 Control 63 96 pos MCF 33
808 1 Control 63 103 pos MCF 40
785 1 Control 63 103 pos MCF 40
149 1 Control 63 107 pos MCF 44
821 1 Control 63 116 pos MCF 53
781 1 Control 63 128 pos MCF 65
861 2 Vaccine 77 152 neg -
702 2 Vaccine 77 152 neg -
214 2 Vaccine 77 153 neg -
774 2 Vaccine 77 153 neg -
769 2 Vaccine 77 153 neg -
090 2 Vaccine 77 154 neg -
967 2 Vaccine 77 154 neg -
968 2 Vaccine 77 154 neg -
165 2 Control 77 110 pos MCF 33
700 2 Control 77 152 neg -
856 3 Vaccine 182 212 pos MCF 30
776 3 Vaccine 182 217 pos MCF 35
965 3 Vaccine 182 224 pos MCF 42
701 3 Vaccine 182 257 pos MCF 75
862 3 Vaccine 182 257 neg non-specific
611 3 Vaccine 182 257 neg non-specific
770 3 Vaccine 182 258 neg -
699 3 Vaccine 182 258 neg -
326 3 Control 182 217 pos MCF 35
023 3 Control 182 250 pos MCF 68
019 4 Vaccine 273 305 pos MCF 32
969 4 Vaccine 273 310 pos MCF 37
613 4 Vaccine 273 315 pos MCF 42
771 4 Vaccine 273 320 pos MCF 47
195 4 Vaccine 273 348 pos MCF 75
966 4 Vaccine 273 348 neg non-specific
768 4 Vaccine 273 349 neg -
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Table 1 Immunisation study groups, treatments and outcomes (Continued)
772 4 Vaccine 273 349 neg -
719 4 Control 273 300 pos MCF 27
620 4 Control 273 302 pos MCF 29
a Vaccinated animals in all groups received the same dose (10 mL of 107 TCID50 per mL) of vaccine for both prime and boost, given intramuscularly with 20% (v/v)
Emulsigen. Control animals in each group received virus-free culture medium with Emulsigen, prepared and administered in the same way.
b Pathogenic AlHV-1 challenge for each group was as follows: group 1 received 10 mL of 104.7 TCID50/mL virus; group 2 received 10 mL of 10
3.8 TCID50/mL virus;
and groups 3 and 4 received 10 mL of 104.05 TCID50/mL virus, administered intranasally in all groups.
c All animals were monitored daily for clinical signs of MCF, including fever, loss of appetite, depression, nasal or ocular discharge and conjunctivitis. A clinical
scoring scheme (Additional file 1 Table S1) was used to ensure that all animals were euthanized at the onset of moderate clinical signs. Animal that did not
develop clinical signs of MCF were euthanized for post-mortem at least 75 days after challenge.
d Pathology was assessed as described in the text and is summarised as MCF, non-specific or negative (−). Tissue sections from animals with non-specific
pathology were tested for presence of AlHV-1 DNA by real-time PCR. No viral DNA was detected in any sample with non-specific pathology.
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muscular (IM, upper neck) immunisation with attenu-
ated AlHV-1 in Emulsigen (20% v/v), while the
remaining eight calves were challenged after mock prime
and boost immunisation with virus-free culture medium
in Emulsigen.
In the second study, the longevity of protection
induced by the vaccine formulated with Emulsigen was
tested by immunisation of three groups of eight calves
(Table 1; groups 2–4) followed by challenge at various
time points after immunisation. In each experiment,
uncoagulated blood and nasal secretions were collected
from all animals just prior to primary immunisation,
fortnightly until challenge and weekly thereafter as
described previously [21].
At autopsy, the following tissues were collected: brain,
buccal mucosa, rumen, reticulum, liver, kidney, lung,
prescapular lymph node, mesenteric lymph node (MLN),
naso-pharyngeal tonsil and blood. Pieces of each tissue
(except blood) were fixed in 10% formal saline before
processing and embedding in paraffin wax. For patho-
logical analysis, 4 μm sections of formalin-fixed tissues
were cut and stained with haematoxylin and eosin. In
addition, total DNA was prepared from blood buffy coat
cells or from sections of selected fixed tissues for PCR
detection of viral DNA.Detection of viral DNA in blood and fixed tissues
Viral DNA was assayed in pure genomic DNA samples
extracted from blood buffy coat cells or from 100 μm sec-
tions of fixed tissues by quantitative (q)PCR as described
previously [25]. Briefly, ~50 ng of total DNA was assayed
simultaneously for the presence of AlHV-1 and genomic
actin sequences by duplex real-time PCR analysis. Each 20
μL assay contained 900 μM of each AlHV-1 forward and
reverse primer (AlHV1-F, AlHV1-R) and 250 μM of the
fluorogenic probe FAM-AlHV1 [25]; 450 μM of each gen-
omic actin primer (gACT-F: 5′-CAC CTT CCA GCA
GAT GTG GA-3′; gACT-R: 5′-CTA GAA GCA TTT
GCG GTG GAC ) and 125 μM of the fluorogenic minor-
groove binding (mgb) probe VIC-gACT (5′-VIC-AGCAAG CAG GAG TAC G-mgb) (K. Willoughby; unpub-
lished data); and real-time PCR reagents containing Plat-
inum Taq polymerase and ROX control dye (Invitrogen).
All assays were conducted using standard conditions on
ABI 7000 or 7500 sequence detection systems (Applied
Biosystems).Analysis of antibody responses by ELISA and virus-
neutralising antibody test
To quantify the humoral antibody response in blood
plasma and the mucosal antibody response in nasal
secretions (NS), an antibody ELISA was developed based
on a detergent extract of the vaccine virus. Virus from
cell-free culture fluid of BT cells infected with attenuated
AlHV-1 C500 was concentrated by centrifugation
(35 000 × g, 3 h, 4°C). Virus pellets were resuspended in
phosphate-buffered saline (PBS) containing 0.8% CHAPS
(3-[(3-Cholamidopropyl) dimethylammonio]-1-propane-
sulfonate, Sigma) and the insoluble virus pellet was col-
lected by centrifugation as above. The virus pellet was
then solubilised in 0.2% SDS before dialysing back into
0.2% CHAPS in PBS. This virus-positive ELISA coating
antigen had a protein concentration of approximately
2 mg/mL. To produce a negative antigen for compari-
son, cell-free culture fluid from uninfected BT cells was
treated according to the same protocol and the resulting
solution used as negative ELISA antigen.
Pairs of adjacent rows of 96-well microtitre plates
(Greiner, high protein binding) were coated with 50 μL
of 5 μg/mL virus-positive or -negative antigen in 0.1 M
carbonate buffer pH 9.6. Individual samples of blood
plasma or sterile-filtered nasal secretion fluid diluted in
PBS were then applied in duplicate to positive and nega-
tive antigen wells at serial dilutions from 1:100 to
1:4000. A standard curve, comprising 1:100 to 1:4000
dilutions of an AlHV-1-positive plasma pool was
included on each plate to ensure reproducibility in the
assays. A negative serum at 1:500 dilution was also
included with each test sample series. Antibody bound
in each well was detected using 1:1000 rabbit anti-
bovine IgG-Horseradish Peroxidase conjugate (Sigma).
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and negative antigen wells for each sample dilution)
were used to calculate a relative titre for each test sam-
ple, based on the standard curve produced from the
positive control serum wells on the same plate. Test
samples with ELISA values outside the range of the
standard curve were discarded.
The virus neutralisation test was based upon inhibition
of AlHV-1-induced cytopathic effect in BT cells by dilu-
tions of plasma or nasal secretion fluid as described
[21,22]. Assays were carried out in 96 well tissue culture
plates with BT cells at greater than 80% confluence. All
assays used a high titre bovine anti-AlHV-1 serum as a
standard and included non-specific toxicity control wells
containing sample and cells without virus.
Pathology and histopathology
MCF was confirmed by clinical and pathological signs. The
clinical symptoms included fever, nasal and ocular dis-
charge, conjunctivitis and development of corneal opacity.
Clinical assessment was done using a system (Additional
file 1 Table S1) which combined scores for pyrexia (1–3),
nasal discharge (0–2), ocular pathology (1–3) and diar-
rhoea (1–6). Any animal with a score over 6 was eutha-
nized without delay. This system ensured that all animals
with clinical MCF were euthanized at a similar stage of the
disease, prior to the development of moderate clinical
signs. All animals with MCF had clinical signs for fewer
than 5 days before euthanasia. Surviving animals were
euthanized 11 weeks after pathogenic virus challenge.
MCF histopathology in brain, kidney, liver, lung and digest-
ive epithelium was examined and scored for the frequency
of lesions consistent with MCF as described [21]. The
pathology of each case was summarised as MCF (most of
the organs studied contained significant numbers of lesions
consistent with a diagnosis of MCF); non-specific (a small
number of lesions, present usually only in one or two stud-
ied organs, and of mild intensity, without extensive infiltra-
tion of lymphocytes or clear vasculitis); or negative (no
significant lesions observed). A positive test for AlHV-1
DNA in the blood on the day of post-mortem, in combin-
ation with MCF histopathological signs, was taken as a de-
finitive diagnosis of MCF. In cases with non-specific
pathology observed in some tissues, DNA prepared from
adjacent sections was tested for the presence of virus DNA
to assess whether the lesions observed could be due to
AlHV-1 infection.
Statistical analysis
Data for post-challenge survival between groups were
analysed by Fisher’s exact test [26,27] while comparison
of immune response data was done by students’ T-test
on log(base2)-transformed titre data. p values less than
0.05 were considered significant.Results
Protection of cattle from MCF by attenuated AlHV-1 in
emulsigen
In these studies, four groups of eight cattle were vacci-
nated with attenuated AlHV-1 C500 in the presence of
20% (v/v) Emulsigen (MVP Labs, USA), while 14 control
animals were mock-vaccinated with adjuvant in tissue
culture fluid (Table 1). Both primary and boost immuni-
sations, using the same material given four weeks apart,
were administered by the intramuscular route, high in
the neck of each animal.
Within groups 1 and 2 (Table 1) a total of 16 vacci-
nated animals were challenged with pathogenic AlHV-1
by the intranasal route at either 9 or 11 weeks after pri-
mary immunisation. Groups 3 and 4, each comprising
eight vaccinated animals and two unvaccinated controls,
were challenged at 26 and 39 weeks, respectively, after
the primary immunisation, by intranasal inoculation of
pathogenic AlHV-1 (Table 1).
Animal rectal temperatures and general demeanour
(appetite, activity, nasal secretion) were recorded daily fol-
lowing challenge and additional clinical scores (Additional
file 1 Table S1) were recorded daily after the onset of fever
(temperature≥ 40°C). A final blood sample was collected
before euthanasia and a range of tissues were collected
post-mortem for diagnostic, pathological and molecular in-
vestigation. Animals that did not succumb to MCF were
euthanized for post-mortem examination between 75 and
77 days after challenge (Table 1).
In groups 1 and 2, challenged at 9 or 11 weeks post
vaccination, 13 animals were protected from clinical
MCF while all but one of the control animals suc-
cumbed to disease. Analysis of these data by Fisher’s
exact test showed that protection was statistically signifi-
cant in each individual study (group 1, p= 0.025; and
group 2, p= 0.003), while the combined results were
highly significant (p< 0.0001), demonstrating the effi-
cacy of Emulsigen as an adjuvant in this system.
In the groups challenged at later times after primary
immunisation, four of eight animals in group 3, chal-
lenged at 26 weeks, and three of eight animals in group
4, challenged at 39 weeks, survived with no disease and
no detectable AlHV-1 DNA post-mortem (Table 1).
Comparison of the occurrence of MCF in the vaccinated
and unvaccinated groups by Fisher’s exact test showed
significant protection was afforded by the vaccine
against MCF challenge at six months after immunisation
(p= 0.04) but not at 9 months (p= 0.12).
Evidence of circulating viral DNA in infected animals
Analysis of terminal blood and tissue samples showed
that all animals with clear clinical and histopathological
signs of MCF (Table 1) had detectable virus DNA in
blood. In contrast, animals that showed no clinical
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defined above (Table 1), had no detectable AlHV-1 DNA
in blood or in tissue sections containing lesions, con-
firming that these animals did not have MCF at the time
of euthanasia. In MCF cases in either vaccinated or con-
trol animals, virus DNA could be detected up to three
weeks before post mortem.
ELISA analysis of antibody responses following
vaccination and challenge
The relative titres of AlHV-1-specific antibodies in nasal
secretions and blood plasma were determined with re-
spect to standard pools of MCF-positive plasma or nasal
secretions using the direct ELISA described above. Ani-
mals in group 1 were assayed independently of the other
groups, using a different serum pool to calculate relative
titre. Thus the ELISA results from group 1 are not com-
parable with the other groups. For animals in groups 2–4,
samples from throughout the study period were tested
together. Unvaccinated control animals challenged withFigure 1 ELISA analysis of virus-specific antibody responses in vaccin
specific antibody titres in plasma (filled squares, solid line) and in nasal sec
animals available at each time point. Error bars correspond to the standardAlHV-1 showed no detectable titre of anti-viral antibodies
at any point before or during the progress of clinical
disease.
Following immunisation and boost, all vaccinated ani-
mals showed a peak in anti-virus antibody titre in both
blood plasma and nasal secretions between days 63 and
91 after primary immunisation (Figure 1). Average titres
then reduced to less than 1/100 in plasma and nasal
secretions by day 120. Analysis of virus-specific antibody
titres in nasal secretions and plasma at a point within
the peak response to vaccination (day 63), showed that
plasma antibody titres were significantly lower on day 63
in animals that went on to develop MCF than in those
that were protected (p= 0.006) while nasal secretion
antibody titres were not significantly different between
these groups. After challenge, the patterns of antibody
response also differed between vaccinated animals that
succumbed to MCF and those which did not (Figures 2
and 3). Animals protected by vaccine showed a generally
stable virus-specific antibody response (Figure 2) withated animals from groups 2–4 prior to challenge. Average virus-
retions (open squares, broken line) were plotted for all unchallenged
error of the means.
Figure 2 ELISA analysis of virus-specific antibodies in vaccinated animals from groups 2–4 that were protected from MCF after
challenge. Average virus-specific antibody titres in plasma (filled squares, solid line) and in nasal secretions (open squares, broken line) are
plotted for all vaccinated and challenged animals that survived to the end of the trial without clinical MCF. Error bars correspond to the standard
error of the means.
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remaining below about 1/300. In contrast, the animals
that succumbed to MCF after vaccination showed an in-
crease in anti-viral antibody titre that preceded the de-
velopment of clinical MCF. This is illustrated in Figure 3
for the nasal secretion antibody responses of the four
animals in group 4 which succumbed to MCF. It is not-
able that the increase in antibody titre is not related to
the timing of challenge but to the onset of MCF in each
animal (Figure 3). Analysis of groups 3 and 4 showed
that vaccinated animals with MCF had significantly
higher anti-viral antibody titres in nasal secretions at the
time of euthanasia (p= 0.03) than animals that were pro-
tected. A similar trend was observed in plasma but this
was not significant (p= 0.07).Virus-neutralising antibody responses
Virus-neutralising antibody titres (VNT) were assayed in
samples from all animals at a selection of time points
and for all terminal samples. Group 2 animals (none of
which succumbed to MCF) did not show a significantincrease in VNT following challenge (Figure 4a); while
animals in groups 3 and 4 that succumbed to MCF had
increased VNT at timepoints after challenge compared
to animals that were protected (Figure 4b, 4c) Thus,
neutralising antibody titres roughly paralleled ELISA
titres and confirmed the observation from ELISA data
that animals which succumbed to MCF after vaccination
(in groups 3 and 4) had lower titres at day 63 (p= 0.03
plasma, p= 0.01 nasal secretions) and higher titres in ter-
minal plasma (p= 0.005) than animals from the same
groups that were protected.Discussion
The data presented in this paper extend previous work
showing that a vaccine based on attenuated AlHV-1 pro-
tected cattle challenged intranasally with pathogenic
AlHV-1 C500 from developing clinical MCF [21]. This
previous study reported that protection could be
obtained by immunisation with vaccine formulated with
Freunds adjuvant, an unlicensed product. We have also
demonstrated that the attenuated virus without adjuvant
Figure 3 ELISA analysis of virus-specific antibodies in the four animals from group 3 that succumbed to MCF after challenge. Relative
titres of antibodies in the nasal secretions of each animal at a range of timepoints after challenge are plotted individually. Each animal is
represented by a different symbol, joined by solid lines. The rightmost point in each line corresponds to the sample collected on the day of post
mortem.
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genic AlHV-1 (G.C. Russell, unpublished data). Here we
show that the licensed oil-in-water adjuvant Emulsigen
can facilitate protection from intranasal experimental
AlHV-1 challenge given up to six months after primary
immunisation.
Analysis of plasma and nasal secretion antibody
responses to vaccination and challenge showed that (i)
unvaccinated animals with MCF had no ELISA-
detectable or neutralising antibody response to AlHV-1
following challenge; (ii) vaccinated animals that were
protected from MCF had significantly higher titres of
virus-neutralising antibodies in both plasma and nasal
secretions at about 1 month after boost than unpro-
tected animals and these titres did not significantly
change after challenge (Figure 4); (iii) in contrast, vacci-
nated animals that succumbed to MCF showed signifi-
cant increases in both total virus-specific antibody andvirus-neutralising antibody during the development of
clinical MCF (Figure 3 and Figure 4).
The lack of a detectable antibody response in unvac-
cinated cattle challenged with AlHV-1 could reflect the
rapid onset of MCF that might prevent the induction of
an immune response to combat the infection. However,
in the experiments reported here, the appearance of clin-
ical MCF in control animals ranged between 21 and
68 days after challenge (Table 1), suggesting that there
was sufficient time for the development of an immune
response in at least some of the infected cattle. These
data confirm and extend the previous observation that
control cattle challenged intranasally did not develop de-
tectable titres of virus-neutralising antibody [21].
In field cases of MCF, virus-specific antibody responses
are reported to be found in 70-80% of samples tested
[22]. The lack of antibody response in some MCF cases
was confirmed in a comparative analysis of MCF-
Figure 4 Virus neutralising titres observed in nasal secretion samples from vaccinated animals in groups 2–4 at a range of time-points.
The arrow above each graph indicates the timing of challenge for that group. Samples from animals in group 2 (panel A) are represented by
squares, group 3 (panel B) by triangles and group 4 (panel C) by circles. Filled symbols represent animals that succumbed to MCF while open
symbols represent animals protected by vaccination.
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of 39 OvHV-2 PCR-positive animals with clinical MCF
were considered serologically borderline or negative
[28]. Additionally, sub-clinical infection with MCF
viruses has been inferred from serological surveys in
which animals from MCF-susceptible species (cattle,
bison, deer) had detectable MCF-specific antibodies or
viral DNA in the absence of disease [29-31]. More re-
cently, experiments using OvHV-2 to infect cattle or
bison showed sub-clinical infection of five cattle, with
seroconversion, and of one bison without seroconver-
sion; while evidence of previous infection was found in
six bison of which two had both detectable anti-MCF
antibodies and OvHV-2 DNA [32,33]. Previous subclin-
ical infection did not appear to reduce susceptibility to
MCF following intranasal challenge.
These observations suggest that infection with MCF
viruses and the ensuing immune response and disease
may be more complex than previously thought, leading
to the development of MCF in some animals without a
detectable virus-specific antibody response. There is a
lack of good transmission and epidemiological work on
MCF that requires to be done to address such issues.
In contrast to the boost to AlHV-1-specific antibody
responses found in vaccinated animals that developed
MCF, vaccine-protected animals did not show a signifi-
cant increase in antibody titres after challenge. This is
likely to be because no virus in immunogenic quantity
was able to penetrate the mucosal barrier of neutralising
antibody to boost the response. This supports the con-
tention that the establishment of a mucosal barrier of
antibody is a mechanism of protection against MCF.
This is reinforced by the observation that protected ani-
mals in groups 3 and 4 had high virus-neutralising anti-
body titres after immunisation compared to animals that
succumbed to MCF. The higher titres are likely to be
associated with longer duration of antibody responses
and hence protection at later time points.
The development of high titre virus-specific antibody
responses prior to the onset of MCF among vaccinated
cattle in these experiments suggests that the develop-
ment of clinical MCF includes the expression of virus
gene products that stimulate an anamnestic immune re-
sponse. Indeed, clinical MCF cases are often charac-
terised by the development of a circulating antibody
response which includes antibodies specific for virus
structural antigens including the major glycoprotein
complex of the viral envelope [34,35]. This is in contrast
to recent suggestions that MCF in rabbits and cattle is
associated with a latent infection of lymphocytes and a
lack of lytic gene expression that would include anti-
genic capsid and envelope proteins [11,36,37]. The pres-
ence of antibodies specific for virus structural proteins
in MCF-affected animals suggests that infection resultsin a pattern of virus gene expression that includes a
number of lytic cycle antigens but without the produc-
tion of infectious virus. It may therefore be inappropriate
to discuss MCF in terms of lytic or latent gene expres-
sion patterns since latency should be defined in the nat-
ural host rather than in MCF-susceptible species that
cannot propagate these viruses.
Current work aims to improve the magnitude and dur-
ation of the protective immune response by the strategic
inclusion of toll-like receptor (TLR) agonists in the MCF
vaccine. In addition, the role, if any, of cytotoxic T cells
in protection against MCF is currently not known and
this is being investigated. The six month window of pro-
tection offered by the current immunisation regime
should be adequate to protect cattle in Eastern and
Southern Africa exposed to wildebeest during the calv-
ing period. This is being studied in field trials in
Tanzania.
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However, any animal with symptoms that compromised its welfare
would be euthanized immediately.
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